Single Components
Partnerships with Q-VANT Biosciences and Inimmune enable SPI Pharma to expand its adjuvant portfolio beyond traditional alum technologies. Together, we offer access to innovative and sustainable saponin-based and TLR4 agonist portfolio, strengthening our position in next-generation vaccine development for human and animal health.
TLR4 Synthetic Agonist
INI-2002 is a fully synthetic, affordable TLR4 agonist that activates innate immune pathways to enhance vaccine efficacy. Available for licensing, it enables the development of advanced adjuvant systems that deliver strong antibody quality, balanced cellular responses, and broad, cross-protective immunity.
Saponin Based Adjuvants
QS-21 and QSap™ VET are saponin-based adjuvants produced using Q-VANT’s sustainable biomass technology. QS-21 is designed for human vaccines, while QSap VET serves veterinary applications—both delivering potent, safe, and supply-secure immune enhancement through scalable, next-generation adjuvant solutions.